The FDA has approved Neurocrine Bioscience's Crenessity for classic congenital adrenal hyperplasia (CAH), the first drug for ...

Recruiting for clinical trials is hard… and expensive. And a large component of that time involves people sifting through ...

Novo Nordisk has started building its first brand-new manufacturing facility in Denmark since the millennium, saying it plans ...

Dermatology specialist Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to ...

In a time when pharmaceutical companies no longer have the economic luxury of decades-long development cycles, indication ...

Essentially, what Concr demonstrates is that training their algorithms on smaller, yet more diverse, data can lead to increased accuracy, due to the broader biological variability within that training ...

The analysis found that across all the 339 appraisals carried out for the new medicines, the median gain in quality-adjusted ...

AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a ...

The pharma industry is always on the lookout for new therapeutic angles that might prove to be a competitive advantage. Ben Hargreaves outlines how oncology is a priority for research, and how ...

A new UK company, called BioOrbit, has been formed with the aim of developing hardware for the manufacture of pharmaceuticals in space. The start-up is focusing on the crystallisation of antibody ...

AstraZeneca has joined the ranks of pharma companies seeking to bring drugs targeting lipoprotein(a) to market, paying $100 million upfront for rights to a drug developed by CSPC Pharmaceutical.

AstraZeneca’s first-in-class pan-AKT inhibitor Truqap was unable to improve overall survival (OS) in a phase 3 trial in triple-negative breast cancer (TNBC), denting the prospects of the new drug.